Cutler Group LP Ardelyx, Inc. Call Options Transaction History

Cutler Group LP

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 01, 2023	SELL	$2.68 - $4.79 $10,184 - $18,202	-3,800 Reduced 73.08%	1,400 $3,000
Q4 2022 Feb 07, 2023	BUY	$1.22 - $2.85 $6,344 - $14,820	5,200 New	5,200 $3,000
Q2 2022 Aug 04, 2022	SELL	$0.51 - $1.17 $3,621 - $8,307	-7,100 Reduced 22.9%	23,900 $0
Q1 2022 Apr 14, 2022	SELL	$0.65 - $1.18 $18,460 - $33,512	-28,400 Reduced 47.81%	31,000 $3,000
Q4 2021 Jan 18, 2022	BUY	$0.86 - $1.7 $46,268 - $91,460	53,800 Added 960.71%	59,400 $3,000
Q3 2021 Oct 26, 2021	SELL	$1.27 - $8.17 $254 - $1,634	-200 Reduced 3.45%	5,600 $0
Q2 2021 Jul 19, 2021	BUY	$6.55 - $8.98 $37,990 - $52,084	5,800 New	5,800 $3,000
Q2 2020 Jul 22, 2020	SELL	$5.37 - $8.11 $11,277 - $17,031	-2,100 Closed	0 $0
Q1 2020 May 07, 2020	SELL	$4.35 - $8.79 $15,659 - $31,643	-3,600 Reduced 63.16%	2,100 $0
Q4 2019 Feb 06, 2020	BUY	$4.23 - $8.29 $6,345 - $12,434	1,500 Added 35.71%	5,700 $12,000
Q3 2019 Oct 28, 2019	SELL	$2.15 - $6.28 $4,300 - $12,560	-2,000 Reduced 32.26%	4,200 $5,000
Q1 2018 May 11, 2018	SELL	$5.05 - $7.9 $3,535 - $5,530	-700 Reduced 10.14%	6,200 $0
Q4 2017 Jan 17, 2018	BUY	$4.85 - $7.8 $33,465 - $53,820	6,900	6,900 $5,000

218

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $799M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.